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• Small molecule analogues (SMAs)
of the immunomodulator, ES-62,
have been produced.
• Two SMAs protect against
oxazolone-induced skin
inﬂammation in mouse ears.
• Protection is associated with
reduced cellular inﬁltration and
collagen deposition.
• Protection is associated with
decreased IFNγ mRNA in the ears.
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A B S T R A C T
ES-62 is the major secreted protein of the rodent ﬁlarial nematode Acanthocheilonema viteae. The mol-
ecule contains covalently attached phosphorylcholine (PC) residues, which confer anti-inﬂammatory
properties on ES-62, underpinning the idea that drugs based on this active moiety may have therapeu-
tic potential in human diseases associated with aberrant inﬂammation. Here we demonstrate that two
synthetic small molecule analogues (SMAs) of ES-62 termed SMA 11a and SMA 12b are protective in the
oxazolone-induced acute allergic contact dermatitis mouse model of skin inﬂammation, as measured
by a signiﬁcant reduction in ear inﬂammation following their administration before oxazolone sensiti-
sation and before oxazolone challenge. Furthermore, it was found that when tested, 12b was effective
at reducing ear swelling even when ﬁrst administered before challenge. Histological analysis of the ears
showed elevated cellular inﬁltration and collagen deposition in oxazolone-treated mice both of which
were reduced by treatment with the two SMAs. Likewise, the oxazolone-induced increase in IFNγ mRNA
in the ears was reduced but no effect on other cytokines investigated was observed. Finally, no inﬂu-
ence on the mast cell populations in the ear was observed.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Amajor cause of occupational skin disease is allergic contact der-
matitis, which accounts for around 20% of all work-related health
complaints. The mouse oxazolone contact hypersensitivity model
is an experimental model system, which is employed to study human
allergic contact dermatitis and indeed, has provided the frame-
work for understanding of the human disease (Jin et al., 2009; Kaplan
et al., 2012; Lundberg et al., 2012).
ES-62 is a glycoprotein secreted by the parasitic rodent ﬁlarial
nematode Acanthocheilonema viteae (reviewed in Pineda et al., 2014).
Its anti-inﬂammatory properties led to it being tested in both the
collagen-induced arthritis (CIA) model of rheumatoid arthritis
(Harnett et al., 2008; McInnes et al., 2003; Pineda et al., 2012) and
the ovalbumin-induced airway hypersensitivity (OAH) model of
asthma (Melendez et al., 2007; Rzepecka et al., 2013) where in both
cases it was found to protect against disease development. That the
molecule’s ability to modulate disease is dependent on its unusual
post-translational attachment of phosphorylcholine (PC) (re-
viewed in Harnett et al., 2010; Pineda et al., 2014) is supported by
PC conjugated to ovalbumin (Harnett et al., 2008) or albumin
(Al-Riyami et al., 2013) being able to mimic ES-62 in protecting
against CIA. Subsequently, a library of drug-like small molecule ana-
logues (SMAs) based around PC was developed, and two of them
termed 11a and 12b (for structures, see Al-Riyami et al., 2013) have
been shown to be protective in the CIA (Al-Riyami et al., 2013; un-
published) and OAH (Rzepecka et al., 2014) models. In this study,
we employed the oxazolone-induced acute allergic contact derma-
titis mouse model to test the ability of SMAs 11a and 12b to
modulate skin inﬂammation. We now show that both 11a and 12b
are effective at reducing ear swelling and this is associated with a
clear reduction in cellular inﬁltration and collagen deposition as
shown by histological analysis.
2. Materials and methods
2.1. Chemical synthesis and preparation of SMAs
Endotoxin-free SMAs 11a and 12b were prepared to ≥95% purity
by HPLC and 1HNIMR as described previously (Al-Riyami et al., 2013).
The SMAs were reconstituted at 100mg/ml in sterile dimethyl sulf-
oxide (DMSO; Sigma-Aldrich) and then diluted in sterile PBS.
Compounds were ﬁlter-sterilised using a Millex-GP (0.22 μm;
Millipore) ﬁlter unit.
2.2. Oxazolone model
Animals were maintained and experimentation was undertak-
en in the Biological Services Unit with the approval of and in
accordance with the Home Oﬃce UK and the Ethics Review Board
of the University of Strathclyde.
On day 0, the ears of 10-week-old BALB/c mice (5/6 per group)
were sensitised with 1% oxazolone (10 μl on each side;
4-ethyoxymethylene-2-phenyloxazolone; Sigma-Aldrich) in
acetone:sesame seed oil (4:1). On days 5 and 6, 1% oxazolone (20 μl)
was applied to the inner and outer surfaces of the right ear and the
same amount of solvent alone to the left ear. Ear thickness was mea-
sured using a calliper before and 1 h and 24 h after challenge. To
ensure that the swelling was due to oxazolone-speciﬁc inﬂamma-
tion, a non-sensitised but challenged control group was included.
SMA 11a (1 μg), 12b (1 μg) or PBS was injected on days −1, 4 and 5
or day −1 only or days 4 and 5 only, subcutaneously. The dose of
1 μg of SMA was chosen as it was previously shown to be effective
in preventing pathology in CIA (Al-Riyami et al., 2013). Animals were
sacriﬁced and the ears harvested on day 6, 1 h after challenge. For
histological analysis, the ears were ﬁxed in 10% formalin for at least
24 h. For mRNA analysis, ears were kept in RNA-Later (Qiagen) and
stored at −20 °C.
2.3. Ex vivo analysis
2.3.1. Histology
Formalin-ﬁxed ears were embedded in OCTmedium (Tissue Tek)
and snap frozen. Tissue sections (7 μm) were then cut using a
cryotome (Fisher Scientiﬁc) and stainedwith haematoxylin and eosin
(H&E) to show cellular inﬁltration and tissue structure, Gomori tri-
chrome to show collagen deposition, and toluidine blue to stainmast
cells in the tissue.
2.3.2. qRT-PCR
Total RNA was extracted using an RNeasy Fibrous kit (Qiagen)
and ≤1 μg of RNA was used to synthesise cDNA (Applied
Biosystems). TaqMan® RT-PCR was performed using the following
TaqMan® Gene Expression Assays: IL-17A (Mm00439619_m1), IFNγ
(Mm01168134_m1), IL-4 (Mm00445259_m1), IL-22 (Mm01226722_g1),
TNFα (Mm00443259_g1) and IL-6 (Mm00446190m1), all fromApplied
Biosystems. Polymerase chain reactions were performed in duplicate
in a StepOne sequence detector (Applied Biosystems). Data analysiswas
performed using the Applied Biosystems sequence detection soft-
ware and samples were normalised to the reference reporter mouse
glyceraldehyde3-phosphatedehydrogenase (GAPDH;Mm99999915_g1)
endogenous control.
2.4. Statistics
Data were analysed by Student’s t test where *p < 0.05, **p < 0.01
and ***p < 0.001.
3. Results
Oxazolone-induced ear inﬂammation – a well-characterised
model of human atopic dermatitis involving sensitisation to and chal-
lenge with oxazolone (Jin et al., 2009; Kaplan et al., 2012; Lundberg
et al., 2012) was employed for testing of the SMAs as described in
Section 2. SMAs 11a and 12b both reduced oxazolone-induced ear
swelling observed after challenge on days 5 (1h after challenge) and
6 (24h after day 5 challenge and h after day 6 challenge), com-
pared to the PBS-treated oxazolone group, when administered on
days −1, 4 and 5 (Fig. 1). Moreover, the protective effects of 11a were
observed on day 5 prior to challenge with the ear swelling being
Fig. 1. The effect of treatment with 1 μg of SMAs 12b and 11a on days −1, 4 and 5
on ear thickness was assessed following sensitisation and challenge with oxazolone.
A non-sensitised control group was also included. The data are obtained from a single
experiment, which is representative of two (11a) and three (12b) independent ex-
periments. **p < 0.01, ***p < 0.001. ** and *** represent a signiﬁcant difference between
12b − (Oxa + 12b) or 11a − (Oxa + 11a) treated and PBS-treated mice sensitised and
challenged with oxazolone (Oxazolone). Results are expressed as ear thickness in
micrometres.
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signiﬁcantly reduced (31.3 ± 1.38% of the increase in ear thickness
observed in the oxazolone group relative to the non-sensitised
control). In detail, reduced increases in ear thickness were ob-
served, both 1 h (11a; 24.53 ± 1.06%; 12b: 70.21 ± 1.19% of the increase
in oxazolone group relative to the non-sensitised control) and 24 h
(11a: 68.1 ± 2.54%; 12b: 82.8 ± 0.63% of the increase in oxazolone
group relative to the non-sensitised control) following the ﬁrst chal-
lenge on day 5, and ears from the animals treated with 11a
(65.6 ± 2.56% of the increase in oxazolone group relative to the non-
sensitised control) and 12b (80.6 ± 0.86% of increase in oxazolone
group relative to the non-sensitised control), after the second chal-
lenge on day 6 also remained signiﬁcantly reduced in size compared
to the oxazolone group (Fig. 1). The data shown are obtained from
a single experiment, which is representative of a number of inde-
pendent studies employing 11a (n = 2) and 12b (n = 3).
Additionally, treatment with SMA 12b before sensitisation on day
−1 only was also tested in two separate experiments. 12b was able
to signiﬁcantly reduce ear swelling 1 h after the ﬁrst challenge on
day 5 (pooled data; oxazolone group: 275.8 ± 2.6 μm (SEM), n = 12;
oxazolone + SMA 12b group: 246.4 ± 6.6 μm, n = 11; p < 0.001) but
was unable to maintain that reduction 24 h after challenge and fol-
lowing the second challenge, no reduction in ear swelling was
witnessed either (results not shown). Treatmentwith 12b only before
challenge on days 4 and 5 only was also undertaken, but 12b was
not able to consistently reduce ear swelling under this protocol
(results not shown).
Elevated levels of IFNγ, IL-4, IL-17A and TNFα mRNA were wit-
nessed in the oxazolone, compared to the non-sensitised group
(Fig. 2a–d). By contrast, there was no difference in the mRNA ex-
pression levels of IL-6 and IL-22 observed in the oxazolone-
treated compared to the non-sensitised group (results not shown).
Treatment with SMAs 11a and 12b (both at 1 μg) on days −1, 4 and
5 caused a signiﬁcant down-regulation of IFNγ mRNA (Fig. 2a). By
contrast, treatment with 11a and 12b did not have any signiﬁcant
effect on the expression levels of IL-4, IL-17A or TNF-α (Fig. 2b–d).
Likewise, the SMAs were also found to have no effect on the steady-
state levels of IL-6 or IL-22 (only 12b tested) detected (results not
shown).
Histological analysis of the ears showed elevated cellular inﬁl-
tration and collagen deposition in oxazolone-treated mice that was
reduced by treatment with the two SMAs (Fig. 3). No clear differ-
ence in the mast cell populations in the ear was observed amongst
any of the groups as indicated by staining by toluidine blue (Fig. 3).
4. Discussion
It is generally accepted that ES-62 is amongst the best
characterised of helminth-derived immunomodulators (Al-Riyami
and Harnett, 2012; Pineda et al., 2014). It has been shown to be active
in mouse models of both allergic, including oxazolone-induced
contact hypersensitivity (Melendez et al., 2007), and autoimmune
Fig. 2. The effect of treatment with 1 μg of SMAs 11a and 12b on days −1, 4 and 5 on mRNA levels of IFNγ (a), IL-4 (b), IL-17A (c) and TNFα (d) from day 6 ears, 1 h after
challenge, as assessed by qRT-PCR where the levels of the gene of interest were normalised to the level of GAPDH. Data are presented as the means ± SEM of the mean of
replicate values pooled from 3 individual experiments. **p < 0.01. **Signiﬁcant difference between 12b- (Oxa + 12b) or 11a- (Oxa + 11a) treated and PBS-treated mice sensitised
and challenged with oxazolone (Oxa). The non-sensitised group is represented by “non”.
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diseases, and has been described as the helminth-derived mole-
cule with most potential for testing in humans for treatment of such
disorders (Erb, 2009). However, ES-62 is a large protein, and there-
fore potentially immunogenic, thus making it an unreliable drug
candidate. However, the data we have acquired over a number of
years indicated that the active component of ES-62 is its PC moiety
andwe therefore subsequently designed a library of synthetic, small,
drug-like compounds based around PC (Al-Riyami et al., 2013). Both
SMA 11a and SMA 12b are too small to be immunogenic and hence
are ideal candidates for more drug-like versions of ES-62 for ther-
apeutic purposes. In this study, we used the mouse model of
immediate-type hypersensitivity to oxazolone to test the activity
of SMAs 11a and 12b against skin inﬂammation.
We clearly demonstrated the ability of both 11a and 12b to
protect against ear swelling when administered on days −1, 4 and
5. We then further explored the protective effects and histological
examination of ear sections from treated animals revealed reduced
levels of cellular inﬁltration and collagen deposition. The signiﬁ-
cance of mast cells during contact hypersensitivity has been reported
to be quite controversial (Kaplan et al., 2012), with conﬂicting reports
regarding their role. Thus, some authors have reported an essen-
tial role for mast cells in contact hypersensitivity whilst others
reported that mast cells were redundant for this (Askenase et al.,
1983; Galli and Hammel, 1984). In this present study, following his-
tological examination, there was no clear difference observed in the
mast cell numbers in the ears when comparing oxazolone-treated,
oxazolone/SMA-treated and control samples. Their numbers were
generally low and this contributed to it being diﬃcult to deter-
mine whether the SMAs are having an effect on mast cell
degranulation. A failure to ﬁnd such an effect would differ from our
previous work employing ES-62 in themodel (Melendez et al., 2007).
However, despite certain of our data obtained to date suggesting
that ES-62, PC-conjugates and SMAs may employ the same mech-
anism of action (Al-Riyami et al., 2013; Rzepecka et al., 2014) some
previous data employing PC conjugates indicate that this might not
always be the case (Harnett et al., 2008). In any case, although it
appears in the present study that the SMAs are working in a mast
cell-independent manner, this does not exclude them from sup-
pressing mast cell responses in other situations in which these cells
may play a role.
Pro-inﬂammatory cytokines such as TNFα, IL-4, IL-6, IFNγ and
increasingly, IL-17 (Cosmi et al., 2014; Incorvaia et al., 2008;
McFadden et al., 2013; Taniguchi et al., 2013; Watanabe et al., 2002)
are likely to play an important role in allergic contact dermatitis
and other inﬂammatory skin conditions. For example, Webb et al.
demonstrated up-regulated levels of TNFα, with a signiﬁcant in-
crease at 4 h in the oxazolone-induced acute allergic contact
dermatitis model. They also showed that IFNγ increased signiﬁ-
cantly at 24 h (Webb et al., 1998). In our study, when examining
mRNA levels, a strong induction of IFNγ, IL-4, IL-17A and TNFα ex-
pression was seen after oxazolone challenge, consistent with the
previous ﬁndings reported for this model (Ahlfors and Lyberg, 2010;
Fujii and Sengoku, 2013; Heo et al., 2015; Webb et al., 1998).
However, only a signiﬁcant reduction in IFNγ levels was wit-
nessed in mouse ears when treatment with SMA 11a or 12b was
undertaken. Of note, a similar reduction in release of the signa-
ture Th1 cytokine IFNγ was exhibited when 11a was tested in CIA
(Al-Riyami et al., 2013) and when peripheral blood mononuclear
cells and synovial ﬂuid membrane cultures from human patients
with RA were pre-exposed to ES-62 (Harnett et al., 2008).
In summary, we ﬁnd that SMAs of ES-62 can be effective in ame-
liorating skin inﬂammation in a mouse model. Taken together our
Fig. 3. Ear sections from non-sensitised, oxazolone and oxazolone/SMA-treated (days −1, 4 and 5) mice were stained with haematoxylin and eosin (H&E) to show cellular
inﬁltration and tissue structure, Gomori trichrome to show collagen deposition, and toluidine blue to stain mast cells in the tissue.
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results suggest that this study represents a good starting point for
the design of a novel class of drugs, which could potentially be used
to treat allergic contact dermatitis.
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